Watch for Adakveo or Oxbryta to Treat Sickle Cell Disease

March 2020

Adakveo (ah-DAK-vee-oh, crizanlizumab) and Oxbryta (oks-BRYE-tuh, voxelotor) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they'll compete with oral Endari (L-glutamine)...which seems to reduce pain crises and possibly hospitalizations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Infection Control Reinforce Infection Control in Light of Coronavirus
Migraine Don't Jump to Ubrelvy or Reyvow for Acute Migraine Treatment
Vitamins & Minerals Share the Latest Answers About Vitamin D
Vaccines Feel Comfortable Using Tdap for Routine Tetanus Vaccinations
Women's Health Stick with Tried and True Treatments for Menstrual Symptoms
Hypertension Be Ready to Manage Patients With Very High BP
Osteoarthritis Help Patients Navigate Osteoarthritis Treatments
Testosterone Weigh Risks and Benefits of Testosterone for "Low T"
Medication Errors Prevent Cases of Mistaken Med Identity
Sickle Cell Disease Watch for Adakveo or Oxbryta to Treat Sickle Cell Disease
Transitions of Care Reduce Errors During Hospital Transitions to Outside Facilities